CINECA IRIS Institutional Research Information System

BOTTICI, VALERIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.066
EU - Europa 3.696
AS - Asia 3.048
SA - Sud America 521
AF - Africa 259
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.898
DE - Germania 1.124
SG - Singapore 966
CN - Cina 916
IT - Italia 803
SE - Svezia 603
HK - Hong Kong 503
BR - Brasile 422
GB - Regno Unito 312
BG - Bulgaria 197
VN - Vietnam 159
AT - Austria 137
CI - Costa d'Avorio 131
RU - Federazione Russa 128
CA - Canada 116
IN - India 102
TR - Turchia 100
FI - Finlandia 93
FR - Francia 78
KR - Corea 66
SN - Senegal 65
JP - Giappone 57
UA - Ucraina 44
AR - Argentina 37
BD - Bangladesh 33
MA - Marocco 30
PL - Polonia 30
MX - Messico 27
NL - Olanda 25
IQ - Iraq 24
ZA - Sudafrica 20
CH - Svizzera 17
BE - Belgio 16
ES - Italia 16
GR - Grecia 16
PK - Pakistan 13
ID - Indonesia 12
IR - Iran 12
PH - Filippine 12
VE - Venezuela 12
CO - Colombia 11
CZ - Repubblica Ceca 11
EC - Ecuador 10
LT - Lituania 10
UZ - Uzbekistan 10
AU - Australia 9
AZ - Azerbaigian 8
MY - Malesia 8
CR - Costa Rica 7
IE - Irlanda 7
IL - Israele 7
SA - Arabia Saudita 7
CL - Cile 6
JO - Giordania 6
PE - Perù 6
PY - Paraguay 6
UY - Uruguay 6
EE - Estonia 5
PA - Panama 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
BH - Bahrain 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GT - Guatemala 3
HU - Ungheria 3
KZ - Kazakistan 3
AL - Albania 2
DK - Danimarca 2
DZ - Algeria 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PS - Palestinian Territory 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AI - Anguilla 1
AO - Angola 1
BZ - Belize 1
ET - Etiopia 1
EU - Europa 1
JM - Giamaica 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
PT - Portogallo 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 13.601
Salva come PNG Salva come JPEG
Città #
Ashburn 766
Dallas 602
Singapore 515
Hong Kong 489
Woodbridge 419
Chandler 409
Santa Clara 396
Fairfield 387
Ann Arbor 294
Houston 275
Milan 218
Shanghai 211
Sofia 196
New York 194
Beijing 188
Seattle 174
Cambridge 146
Wilmington 142
Abidjan 131
Vienna 125
Los Angeles 115
Munich 114
Princeton 98
Boardman 95
Lawrence 76
Florence 75
Frankfurt am Main 74
Hefei 74
London 73
Ottawa 72
Dakar 65
Pisa 61
Rome 59
Seoul 57
Serra 55
Medford 53
Bremen 45
São Paulo 44
Jacksonville 42
Dearborn 41
Des Moines 41
Boulder 40
Nanjing 40
Izmir 39
Istanbul 38
Tokyo 38
Dong Ket 36
Redondo Beach 35
Lancaster 34
Buffalo 33
Redwood City 33
Ho Chi Minh City 32
Redmond 32
Helsinki 29
San Diego 28
Fuzhou 24
Turku 24
Casablanca 22
Warsaw 20
Changsha 18
Washington 18
Denver 17
Guangzhou 17
Phoenix 17
Belo Horizonte 16
Brussels 16
Montreal 16
Atlanta 15
Ogden 15
Toronto 15
Boston 14
Hanoi 14
Baghdad 13
Bengaluru 13
Council Bluffs 13
Nanchang 13
Quanzhou 13
Bern 12
Düsseldorf 12
Nuremberg 12
Rio de Janeiro 12
Amsterdam 11
Brooklyn 11
Chengdu 11
Jiaxing 11
Johannesburg 11
Lucca 11
Orem 11
Paris 11
Scandicci 11
Chiesina Uzzanese 10
Poplar 10
San Francisco 10
Dhaka 9
Falkenstein 9
Hangzhou 9
Lauterbourg 9
Tashkent 9
Brno 8
Chicago 8
Totale 8.794
Salva come PNG Salva come JPEG
Nome #
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 270
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 241
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 235
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 230
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 224
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Targeted Therapy in Thyroid Cancer: State of the Art 210
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 209
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 206
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 206
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 200
RET point mutations in Thyroid Carcinoma 196
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 188
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 184
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 183
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 179
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 179
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 178
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 173
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 168
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 167
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 163
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 162
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 162
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 162
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 161
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 161
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 159
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 157
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 157
Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer 155
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 154
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 153
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 151
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 151
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 148
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 147
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 146
null 146
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 143
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 141
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 140
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 138
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 137
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 135
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 132
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 131
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 130
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 130
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 129
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 123
null 122
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 118
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 116
null 114
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 114
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 114
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 113
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 113
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 112
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 112
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 111
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 110
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 108
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 103
null 103
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 102
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 100
null 99
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 98
Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastasis. 94
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 90
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 89
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 88
null 86
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 72
null 70
null 70
Ret Oncogene and Thyroid Carcinoma 68
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 66
Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. 62
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study 59
Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. 56
Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform ¹³¹l ablation 52
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 41
Totale 13.795
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.207
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.207
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021391 0 0 0 0 0 58 44 48 49 54 32 106
2021/20221.009 37 45 18 69 204 122 39 45 53 46 74 257
2022/20231.738 206 279 141 129 146 188 31 109 360 17 116 16
2023/20241.107 101 105 154 62 131 223 84 36 14 17 62 118
2024/20253.161 19 112 51 206 349 324 256 164 303 394 302 681
2025/20262.539 333 650 445 393 431 287 0 0 0 0 0 0
Totale 13.795